Nanjing Youke Biopharmaceutical Joint-stock Co., Ltd. is an innovation-driven pharmaceutical company centered on the research and development of innovative drugs with independent intellectual property rights, integrating R&D, production and marketing as a high-tech enterprise. Youke Biopharma has four wholly-owned subsidiaries: Nanjing Youke Pharmaceutical Co., Ltd., Nanjing Libowei Pharmaceutical Co., Ltd., Nanjing Youke Biopharmaceutical Research Co., Ltd. and Shanghai Liwei Pharmaceutical Technology Co., Ltd.
Based on the current situation and development trends of the international pharmaceutical market, the company has established a development focus on raw materials and related formulations of national Class I and Class II new drugs with independent intellectual property rights, with anti-drug-resistant infection drugs, cardiovascular and cerebrovascular drugs, anti-tumor drugs and tumor adjuvant therapy drugs, and gastrointestinal therapeutic drugs as the main lines of development, breaking through key R&D links and technologies such as pharmaceutical chemical synthesis and pharmacological research.
The company is equipped with nearly 2,000 square meters of high-standard R&D laboratories, including pharmaceutical synthesis laboratories, pharmaceutical analysis laboratories, and pharmaceutical formulation laboratories, and has built R&D platforms including the Jiangsu Provincial Enterprise Academician Workstation, the Jiangsu Provincial Recognized Enterprise Technology Center, and the Jiangsu Provincial Engineering Technology Research Center for Anti-Severe Infection Drugs. The R&D center built by the company in Jiangsu Life Science and Technology Innovation Park has a construction area of more than 9,100 square meters, including an anti-infective drug technology platform, a tumor molecular targeted drug platform, and a therapeutic monoclonal antibody R&D platform.
The company has so far obtained 55 domestic patent authorizations, 24 drug production approval numbers, 4 new drug certificates, and has 43 projects under research as well as 46 drug clinical trial approvals, and has obtained 72 drug registration application acceptance numbers.
The company has core competitiveness and rich product reserves in the anti-infection field. The company's main products currently sold include the patented first generic drug moxifloxacin hydrochloride injection (trademark name: Baimeinuo), the national Class I new drug cefoperazone sodium and tazobactam sodium for injection (8:1) (trade name: Leling), and the national Class I new drug ceftriaxone sodium and tazobactam sodium for injection (trade name: Youteneng), etc.
Beautiful life, created by technology. Youke has always adhered to the business philosophy of "for the health of more people, continuously seeking and manufacturing safer and more effective drugs, and cheering for life", with the goals of becoming the "industry* in anti-infective drug innovation and promotion", "a leading manufacturer of Chinese formulations and API exports", and "a first-class innovative pharmaceutical enterprise in targeted drugs and tumor drugs in China", committed to innovation, working hard, and continuously achieving new leaps and breakthroughs in enterprise development.
What does Nanjing Youke Pharmaceutical Co., Ltd. require? Who is Youke Biopharma hiring? Youke Biopharma recruitment: Sales占比最多占60.3%,其次是Biology/Pharmaceutical/Chemical/Environmental Protection占19.3%. What education can get in at Youke Biopharma? 本科占比最多占89%,其次是硕士占7.1%. High education required at Youke Biopharma? 硕士占7.1%,博士占2.5%. Work experience required at Youke Biopharma? 1-3年占比最多占49.9%,其次是5-10年占22.7%. Where are the job locations at Youke Biopharma? 南京占比最多占32%,其次是成都占3.4%. Based on job postings from the past year, for reference only.
Congratulations, submitted successfully!
Your edit is under review. You will be notified by email within 1 business day.
Submission failed.
Help others learn about this company, add my impression of this company»
Log in with the following accounts to save your follows